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Background: Breast cancer is a very heterogeneous disease and some patients are cured by the surgical removal of
the primary tumour whilst other patients suffer from metastasis and spreading of the disease, despite adjuvant therapy.
A number of prognostic and treatment predictive factors have been identified such as tumour size, oestrogen (ER) and
progesterone (PgR) receptor status, human epidermal growth factor receptor type 2 (HER2) status, histological grade,
Ki67 and age. Lymph node involvement is also assessed during surgery to determine if the tumour has spread which
requires dissection of the axilla and adjuvant treatment. The prognostic and treatment predictive factors assessing the
nature of the tumour are all routinely based on the status of the primary tumour.
Results: We have analysed a unique tumour set of fourteen primary breast cancer tumours with matched synchronous
axillary lymph node metastases and a set of nine primary tumours with, later developed, matched distant metastases from
different sites in the body. We used a pairwise tumour analysis (from the same individual) since the difference between the
same tumour-type in different patients was greater. Glycopeptide capture was used in this study to selectively isolate and
quantify N-linked glycopeptides from tumours mixtures and the captured glycopeptides were subjected to label-free
quantitative tandem mass spectrometry analysis. Differentially expressed proteins between primary tumours and matched
lymph node metastasis and distant metastasis were identified. Two of the top hits, ATPIF1 and tubulin β-chain were
validated by immunohistochemistry to be differentially regulated.
Conclusions: We show that the expression of a large number of glycosylated proteins change between primary tumours
and matched lymph node metastases and distant metastases, confirming that cancer cells undergo a molecular
transformation during the spread to a secondary site. The proteins are part of important pathways such as cell adhesion,
migration pathways and immune response giving insight into molecular changes needed for the tumour to spread. The
large difference between primary tumours and lymph node and distant metastases also suggest that treatment should be
based on the phenotype of the lymph node and distant metastases.
Keywords: Breast cancer, Lymph node metastases, Distant metastases, Biomarkers, Glycopeptide capture, Secreted proteins,
Membrane proteins, Mass spectrometry* Correspondence: peter.james@immun.lth.se; emma.nimeus@med.lu.se
1Department of Immunotechnology, House 406, Medicon Village, SE-223 81
Lund, Sweden
2Division of Oncology and Pathology, Department of Clinical Sciences Lund,
Lund University, Medicon Village, SE-223 81 Lund, Sweden
Full list of author information is available at the end of the article
© 2015 Kurbasic et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Kurbasic et al. Clinical Proteomics  (2015) 12:13 Page 2 of 14Background
Breast cancer is the most common cancer among women
and approximately 1500 women in Sweden die from the
disease every year. Although the prognosis has improved
during the last decade, there is still today no curable treat-
ment for patients with a spread to distant sites. In order to
prevent the development of distant spread, a combination
of local and systemic treatment is used, and the choice is
mainly based on the characteristics of the primary tumour
[1]. The presence of lymph node metastases is investigated
with sentinel node or a combination of sentinel node and
axillary dissection, operations performed at the same time
as the primary surgery.
Distinct genes and pathways within a given subtype of
breast cancer, that appear to play an important prognostic
role with regard to metastatic behaviour, have been identi-
fied such as the S100 and EpCAM families [2]. Some micro-
metastatic foci will ultimately form macroscopic tumours
due to their ability to recruit the necessary stroma and vas-
culature. They somehow avoid detection by the immune
system and elimination [3]. Tumour development is essen-
tially Darwinian, in that any of a number of molecular path-
ways that have been selected for in a specific tumour cell
can contribute to the ‘successful’ metastatic tumour [4].
Moreover, this heterogeneity is dynamic, as selective pres-
sures change (that is, in the new environment encountered
by a metastatic cell in a secondary tissue site). Metastasis to
axillary lymph nodes have been shown to be the most im-
portant independent prognostic factor and thus a risk factor
for development of distant metastases in breast cancer [5,6].
Relatively few studies have investigated the changes oc-
curring during the evolution of metastasis in comparison to
the primary tumour. Prognostic factors and molecular sub-
types have been investigated, comparing the primary
tumour and synchronous lymph node metastases and com-
paring the primary tumour to both synchronous lymph
node metastases and asynchronous distant metastases [7,8].
The shift in prognostic factors and molecular subtype was
shown to be of clinical importance and indicated that bio-
markers in the synchronous and asynchronous lymph
nodes and distant metastases may affect the choice of treat-
ment [9,10].
Another recent report [11] demonstrated how next gener-
ation sequencing can be used to determine the occurrence
of somatic mutations occurring during the development and
progression of lobular breast cancer. Using DNA and RNA
re-sequencing, 32 somatic non-synonymous mutations in a
metastatic tumour were found, 19 of which were not
present in the primary lesion. In addition, RNA sequencing
detected two new RNA editing events that recode the amino
acid sequences of two proteins, SRP9 and COG3.
Mass spectrometric analysis has also been performed
using 2-DE in two studies with matched primary breast
tumour and lymph node metastases. In one of the studies,also using CGH array, there were similarities between the
primary tumour and the lymph node metastases although
distinct changes in the levels of individual proteins were
shown (13 pairs), [12] whereas the other study showed lar-
ger differences in protein expression (5 pairs) [13]. Matching
of the primary tumour and later developed distant recur-
rences is rare since the relapses normally are not operated.
Dumont et al. matched one patient with the primary
tumour and a bone metastasis and found significantly regu-
lated surface proteins [14].
In the present study, we collected matched primary tu-
mours with synchronous lymph node metastases and asyn-
chronous distant metastases. This unique tumour set was
then enriched by a glycocapture approach [15] to enable a
proteomic analysis of an interesting sub-proteome. Glyco-
proteins are normally present in the plasma membrane, the
extracellular-matrix or are secreted to the extra cellular
space, and may thus be found in the blood. They are also
known to mediate cellular processes important to cancer
progression such as cell-to-cell signalling, growth, differen-
tiation and migration [16,17]. The glycoprotein enriched
samples were then analysed with liquid chromatography
tandem mass spectrometry (LC-MS/MS) and were quanti-
fied with a label-free approach to find differentially regu-
lated proteins, which can give a molecular insight in how
the primary tumours evolves to metastatic potential. The
differentially regulated proteins may also be exploited as
biomarkers or treatment targets. Two of the top regulated




Samples were collected from 14 patients with tissue from
the primary tumour and synchronous lymph node metas-
tases (LNM) and 9 patients with tissue from a primary
tumour and the distant metastasis (DM). LNM was de-
fined as cancer involved lymph nodes in the ipsilateral ax-
illa and DM as other sites than the ipsilateral breast or
axilla. Two patients in the DM group had two samples,
one had two skin metastases and one had metastases to
the lung and to the ipsilateral breast (local recurrence).
Most often distant metastases are not removed so the
number is limited; however it is the largest proteomic
study of its kind to be presented, to the best of our know-
ledge. The patient characteristics are given in Table 1, and
the sites of primary tumours, lymph node metastases and
distant metastases in this study are schematically shown
in Figure 1(a).
Breast cancer is a heterogeneous disease at the patho-
logical and histological level [18], and falls into at least 5
molecular subtypes (Luminal A and B; Basal; Her2 and
normal), [19] and possible a sixth less abundant type, (low
Claudin) [20] which greatly affect the prognosis [21].
Table 1 Patient characteristics
Lymph node metastasis Distant metastasis
Number of patients 14 9
with 2 samples 14 7
with 3 samples 0 2
























aOf the primary tumour.
bOf the metastasis.
cOne patient had an ER+ primary tumour and an ER- distant metastasis.
dAfter primary surgery.
eBefore primary surgery.
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proach in which both tumours come from the same pa-
tient. This allows a direct comparison of how the primary
tumour has evolved to the lymph node and distant metas-
tases. The experimental flow is shown in Figure 1(b).
We chose to focus on changes in glycoprotein expression
during tumour progression. This allows us to focus on pro-
teins from the plasma membrane, extracellular matrix and
secreted proteins that are known to be important for cancer
progression.
After glycopeptide enrichment, label-free LC-MS/MS
was performed to identify and quantify the glycopeptides.
Statistical and pathway analysis was performed to analyse
the differences between primary tumours and the matchedmetastases. Finally, we verified the accuracy of LC-MS/
MS with immunohistochemistry and validated two pro-
teins to be differentially regulated.
Variation in glycoprotein expression between the primary
tumour and metastases
The effect of pairing samples using the example of one
protein, platelet endothelial cell adhesion molecule is
shown in Figure 2(a), and how it varies between primary
(blue dots) and distant metastases (red dots) and be-
tween patients. If a paired analysis would not have been
used the effect of the change in expression level would
have been masked. In this study, we had access to paired
primary—lymph node metastases and primary-distant
Figure 1 (a) A representation of cancer spread from primary tumour to synchronous lymph node metastases or asynchronous distant metastases. This
figure shows a schematic representation of the spread of cancer from the primary tumour to the lymph nodes and distant sites for the samples in this study,
which are lung, ipsilateral and contralateral axillary lymph nodes, bone and skin and in the greater oment. (b) Experimental design overview.
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evolution. Thus, we hypothesized that the difference be-
tween primary-lymph node should be smaller than the
difference between primary-distant. Figure 2(b) shows a
box plot representation of the difference between paired
tumours for both primary—lymph node and primary-
distant paired tumours, as correlation distance. The lar-
ger distance in the distant recurrence group, although
not statistically significant corresponds to a larger differ-
ence between primary-distant tumours.Figure 2 A paired analysis approach using tumours from the same patient wa
Log2 abundance of P16284, platelet endothelial cell adhesion molecule, for prim
representation of the correlation distance between paired tumours; primary-lymDifferences in glycoprotein expression between the
primary tumour and metastases
After raw mass spectra were aligned and peptide se-
quences identified, a Mascot search against the Uniprot
database (release 2012, filtered for Human) identified
over 2300 glycoproteins with a FDR < 0.05. Normalisa-
tion by total ion current in the analysis area and quanti-
fication was carried out in Progenesis. DM and LNM
groups were analysed separately and Figure 3 shows pro-
teins that are significantly regulated between primarys used. (a) An example of the paired analysis showing the protein levels.
ary tumour (blue dots) and distant metastasis (red dots). (b). A box plot
ph node metastasis and primary-distant metastasis.
Figure 3 Protein expression changes between the primary tumour and lymph node metastases and distant metastases.
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significance (p < 0.01). Further analysis of the changes
occurring between glycoprotein expression in the pri-
mary tumour and the lymph node metastases is shown
in Figure 4(a). Principal component analysis (PCA) of
the changes occurring in glycoprotein expression be-
tween primary and LNM pairs was performed to show
patterns of similarity between tumours. There is a weak
tendency for the primary tumours to group together in
the lower half of the figure with the lymph node metas-
tases occurring in the top half. However there is large
inter-patient variation, which is the dominant effect. The
same effect is seen in the PCA plot in Figure 4(b), show-
ing DM tumour pairs. Here the effect is even more pro-
nounced where tumour pairs are relatively close and no
obvious clustering for stage or tissue/relapse site. This is
in line with the idea that breast cancer is a very hetero-
geneous disease and that changes between a primary
tumour and the metastases is peculiar to each tumour
pair, supporting the rationale for analysing tumours pair-
wise. It also demonstrates that the tumours do not clus-
ter on tissue, which is a risk when analysing tumours
from different sites in the body. Figure 5 shows the two
patients that have three samples. Patient 1 (red) has one
recurrence in the skin in the ipsilateral breast, and one
in the lung, while patient 5 (blue) have two recurrences
in the skin. This figure demonstrates that there is aFigure 4 Principal component analysis shows the degree of relationship betwe
Principal Component Analysis of primary and lymph node metastasis pairs. A ci
(b). Principal Component Analysis of primary and distant metastasis pairs. A circlarger difference between the two patients than between
different stages of cancer (primary tumour—distant me-
tastases). It also demonstrates that the two skin metastases
from patient 5 are very similar, while the two recurrences
from patient 1 are more different. This could be explained
by that different changes are required for the ability to
metastasize to specific sites. Possibly it is the same clone
that has metastasized from patient 5 and two different
clones from patient 1.
Differences in glycoprotein expression patterns between
the primary tumour and metastasis could possibly be
modified by any treatment given between the two samples.
In this study, several patients received adjuvant treatment
(Table 1). However, there were too few patients to study
the effect of different treatments and we thus focused on
the overall change of glycoproteins. In future studies, it
would be of great interest to focus on the effect of specific
treatments.
Functional and pathway differences between the primary
tumour and metastases
Among the differentially regulated proteins, there are clear
groupings of proteins, for example those that are involved
in the progression from primary tumour to lymph metasta-
sis and distant metastasis, include many with motility func-
tions. Cell migration-inducing gene 3 is up-regulated and is
known to function as a cell migration-inducing gene 3en the primary tumour and the corresponding paired metastasis. (a).
rcle indicates a primary tumour and a triangle the lymph node metastasis.
le indicates a primary tumour and a triangle the distant metastasis.
Figure 5 Principal Component Analysis of primary, lymph node and distant metastasis within two patients with triple samples. Red indicates
patient 1 with one distant metastasis in the lung and one local recurrence and blue patient 5 with two skin metastases.
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Uniprot (Q9BSJ5-1). Protocadherin is involved in homophi-
lic cell adhesion that allows tumour cells to move out into
the blood and migrate to bone [22] as is the neuronal cell
adhesion molecule (NCAM) [23] and both are up-regulated
in lymph and distant metastasis. Platelet endothelial cell
adhesion molecule (PECAM) also binds cells together
but in addition is required for promoting the migration
of leucocyte migration across the endothelium [24].
Metastasis-associated in colon cancer protein is strongly
down regulated in lymph node metastasis but up regu-
lated in distant metastases. It promotes cell motility,
proliferation and hepatocyte growth factor (HGF)-
dependent scattering in vitro and tumour growth and
metastasis in vivo (Uniprot Q6ZN28). This suggests that
targeted methods could be developed to prevent disper-
sion at an early stage.
The proteins showing significant down-regulation such as
Serum paraoxonase/arylesterase 1 (PON1) has been associ-
ated with increased vascularisation in retinopathy [25] as
well as increased risk for prostate cancer [26] but in breast
cancer down-regulation is associated with lower survival
time in patients with clinical recurrence of breast cancer
[27]. Down regulation is seen for many proteins involved inimmune response such as CD82 antigen, Ig alpha-2 chain C
and Ig kappa chain C though the MHC antigens class I anti-
gen A*26, Cw*4 and Cw*15 are up-regulated.
Changes in hormone receptor signalling pathways
Oestrogen receptor alpha (ER) is a nuclear receptor for
the steroid hormone oestrogen. It is one of the clinically
most important determinants of prognosis and response
to endocrine treatment. The presence or absence of this
receptor has a profound effect on the biology of the can-
cer cell and at the RNA-level, it is one of the strongest
separators for clustering [28]. We therefore wanted to
analyse the differences of glycoprotein expression be-
tween ER+ and ER- tumours.
Using clinical routine methods one of the patients (D3)
reversed the ER status, which had an ER+ primary tumour
and an ER- DM. This phenomenon has been investigated
by immunohistochemistry [29] showing that 33% of pa-
tients with breast cancer show a reversal of ER or PgR sta-
tus and 15% of patients experience a change in HER2
status between primary tumour and recurrence. Of clinical
relevance is that ER+ patients at relapse can be treated with
endocrine therapy and have better prognosis than ER- pa-
tients, independent of the ER status of the primary tumour.
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occurring in hormone signalling. The program displays
a thermometer indicating the change in expression of
the protein in the lymph node metastasis or distant me-
tastasis relative the paired primary tumour. One path-
way that scored high and is of great clinical importance
is the development of oestrogen receptor ligand inde-
pendent activation. For the analysis, the protein expres-
sion was normalised against the whole primary tumour
data set. Additional file 1: Figure S1(a) shows the
changes in expression of the main actors in ligand inde-
pendent activation (EGFR (Epidermal growth factor re-
ceptor, HER2), ErbB2 (Receptor tyrosine-protein kinase
erbB-2) ErbB3 (Receptor tyrosine-protein kinase erbB-
3), IGFR1 (insulin-like growth factor receptor-1), Shc
(Shc transforming protein-1), NCOA2 (nuclear receptor
co-activator-2), TFF1 (Trefoil factor 1) and PKA-reg
(protein kinase A regulatory subunit)) in a comparison
between ER+ and ER- lymph node metastasis, relative
to the primary tumour. The protein Trefoil factor 1 is
under control of the oestrogen receptor and is up regu-
lated in the ER+ lymph node metastasis but clearly
down-regulated in the ER- lymph node metastasis.
However this is reversed in the distant metastases as
seen in Additional file 1: Figure S1(b) probably as a re-
sult of the strong up-regulation of TFF1 in the ER- and
of the down-regulation of the nuclear receptor co-
activator-2. The effect seems to develop during the evo-
lution of ER- lymph node metastasis to distant metasta-
sis as seen in Additional file 1: Figure S1 (c). In contrast,
in Additional file 1: Figure S1(d) no effect is seen in the
change from ER+ lymph node metastasis to distant me-
tastasis since oestrogen signalling is still intact.
Immunohistochemical verification of mass spectrometry
results
In order to verify the accuracy of the mass spectrometry
results, five of the top regulated proteins were chosen for
further validation with immunohistochemistry (IHC): mito-
chondrial ATPase inhibitory factor 1 (ATPIF1), CD82, kera-
tin type I cytoskeletal 17 (CK17), thrombomodulin and
tubulin β-chain. Proteins were selected based on antibody
availability from companies that usually provide high-
quality anti-bodies. The expression was scored in 5 levels
(0–4) on a tissue micro array (TMA) from a separate co-
hort of 552 primary tumours, 159 matched synchronous
lymph node metastases and 51 matched asynchronous me-
tastases (locoregional or distant). Patient characteristics are
found in the original study [30,31]. The distribution of the
intensities for the five proteins can be seen in Table 2. Rep-
resentative staining intensities are shown in (Figure 6 a-b).
For ATPIF1, we were able to score 126 tumour pairs,
which showed a significant decrease in intensity from the
primary tumours to the lymph node metastases (p = 2.8e-09) (Figure 7a). This was consistent with the down regula-
tion found with mass spectrometry. For tubulin β-chain, we
were able to score 121 tumour pairs, which showed a de-
crease in expression intensity from primary tumour to
lymph node metastases (p = 3.5e-05) (Figure 7b). This is also
consistent with the mass spectrometry observed down regu-
lation. The IHC staining intensity was very low of the
remaining antibodies; (thrombomodulin, CK17 and CD82)
and we found that it was not possible to compare primary
tumours and metastases (Table 2), as a large majority scored
0 intensity. This was despite great effort to optimize the
IHC protocol. Thus, the IHC analysis was able to verify the
decrease of ATPIF1 and tubulin β-chain expression seen
with mass spectrometry, while CD82, CK17 and thrombo-
modulin analyses were excluded due to poor staining.
ATPIF1 is the inhibitor of the ATP synthase, which pro-
vides the majority of oxygen necessary for sustained cellular
activity [32]. Previously, it has been shown that ATPIF1 is
overexpressed in human carcinomas, blocking the ATP syn-
thase and decreasing the ATP production. This stimulates
aerobic glycolysis, which in cancer cells is known as the
Warburg phenotype [33,34]. Such reprogramming of the
cellular energy metabolism is considered to be an emerging
hallmark of cancer. Although it is known that ATPIF1 is
overexpressed in several carcinomas, it is more difficult to
find studies investigating and comparing the expression of
ATPIF1 in primary tumours and lymph node and distant
metastases [35]. Although the Warburg phenotype has been
shown to stimulate metastasis, we see a decrease in ATPIF1
expression from primary tumour to lymph node metastasis.
One explanation could be that the expression of ATPIF1
levels out after induction of metastasis, and only increases in
expression during the transformation process from normal
cell to tumour cell.
Tubulin β-chain builds up heterodimers of tubulin, which
in turn are the major components of microtubules. Microtu-
bules play a very important role in formation of the mitotic
spindle, which separates the chromosomes during cell
division. Furthermore, microtubules are crucial constituents
of the cytoskeleton, making them important facilitators of
transport and cell motility [36]. This also makes them good
targets for cancer therapy, so called anti-mitotics, which
bind to β-tubulin and disrupt the microtubules in the mi-
totic spindle. This prevents separation of the sister chroma-
tids and hence halts mitosis [37]. The reason for a decreased
level of β-tubulin in lymph node metastases is not obvious
and needs to be further studied. However, here it is found in
two separate patient cohorts, and with two independent
techniques.
Conclusions
In this study we compared differential glycoprotein expres-
sion in a unique set of matched tumour pairs, 14 lymph
node metastases and 9 distant metastases. We used a paired
Table 2 Immunohistochemical staining intensities
Intensity ATPIF1 Tubulin β-chain CD82 CK17 Thrombomodulin
Primary tumour 126 121 121 122 117
0 1 6 96 144 89
1 10 29 23 5 23
2 34 56 2 2 4
3 49 22 0 0 1
4 32 8 0 1 0
Synchronous lymph node metastasis 126 121 121 122 117
0 3 8 85 116 91
1 21 54 33 2 24
2 55 49 3 3 1
3 33 9 0 1 1
4 14 1 0 0 0






Kurbasic et al. Clinical Proteomics  (2015) 12:13 Page 9 of 14approach and showed a large difference in glycoprotein ex-
pression between the primary tumour and its matched me-
tastases, as well as large interpersonal differences.
Further, the glycoproteins here found to be differen-
tially regulated gives an important insight into the evo-
lution of a primary tumour towards the spreading of the
disease as seen by changes in cell adhesion and migration
pathways and immune response. We also demonstrate the
glycoprotein difference between ER+ and ER- and that ER
ligand independent activation seems to be an important
pathway. Finally, we validated the differential expressionFigure 6 This show representative images of intensity grading levels. Tissue co
a) Staining of ATPase Inhibitory Factor 1 levels 0–4 b) IHC staining of tubulin β-of two glycoproteins: ATPIF1 and β-tubulin which con-
firms the validity of the mass spectrometry results and
that loss of ATPIF1 and β-tubulin may be important
events for a breast cancer to be able to metastasize.
In summary, there are substantial changes at the
glycoprotein level during tumour development indicat-
ing that future research should be aimed at the biology
of the metastasis to be able to tailor treatment accord-
ing to the characteristics of the metastases, since treat-
ment strategies are normally based on the primary
tumour.res are 1.0 mm and the images were taken with 40× magnification.
chain intensity levels 0–4.
Figure 7 This shows the change in immunohistochemistry intensity between primary tumours and lymph node metastasis. Wilcoxon signed-rank test for
paired samples were performed to assess statistical significance. Red line represents the mean. a) The expression of ATPase inhibitory factor 1 significantly
decrease (p = 2.8e−09). b) The expression of tubulin β-chain significantly decreases (p = 3.5e−05).
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Materials
All HPLC solvents, Ammonium bicarbonate, 2,2,2-Trifluor-
oethanol (TFE), Dithiothreitol (DTT), N-acetyl-cysteine
and iodoacetamide (IAA) were purchased from Sigma
Aldrich (Stockholm, Sweden). Criterion Precast SDS-PAGE
gels (12.5%) and Affi-Prep Hydrazide Hz resin supplied as
50% slurry in isopropanol were from BioRad (Hercules,
CA, USA). Protein Desalting Spin Columns and Sodium
meta-periodate were acquired from Pierce (SDS diagnos-
tics, Falkenberg, Sweden). UltraMicroSpin C18 and Ultra-
MacroSpin C18 columns were from the NestGroup
(Southborough, MA, USA). Sequencing grade modified
Trypsin was purchased from Promega (Madison, WI,
USA), Zirconia beads from BioSpec Products, Inc. (Bartles-
ville, OK, USA). RapiGest and Sep-Pak C18 from Waters
(Milford, MA, USA). PNGase F and Protease Inhibitor
cocktail were acquired from Roche Gmbh (Mannheim,
Germany).
Patient data
Frozen samples from 23 patients were retrieved from the
bio bank of the Department of Oncology, Lund University
(Table 1). The criteria for selection were to have both a
primary breast tumour sample and a sample from a lymph
node metastases or distant metastases stored in the bio
bank. We divided the patients into two groups, based on
the type of metastasis. The first group had lymph node
metastasis (LNM) (i.e. in the in the ipsilateral axilla) and
the second group had distant metastasis (DM) (i.e. at any
other site than the same breast and the ipsilateral axilla).
We further divided the DM group based on site of the re-
currence: abdomen (usually the greater oment), lung, skel-
eton, skin, contralateral axilla and ipsilateral breast. Twopatients had 3 samples, one with a primary tumour and
two distant metastases in the skin, and one with a primary
tumour and metastasis to the lung as well as a recurrence
in the same breast (local recurrence). The patient with a
local recurrence was included in the DM group since this
patient also had a lung metastasis. The local recurrence
was included in the PCA plot for visualisation but was ex-
cluded from the comparison between primary tumour
and distant metastasis.
The patients underwent primary surgery, either mastec-
tomy or breast conserving surgery, in the South Sweden
health care region between the years 1987–2000. They ob-
tained standard of care after primary surgery, which for
the DM group means between the primary tumour and
distant metastasis. The treatment given was adjuvant
radiotherapy (DM: 22%, LNM: 78%), adjuvant endocrine
therapy (Tamoxifen, aromatase inhibitor, oophorectomy
or radio castration) (DM: 22%, LNM: 64%) and adjuvant
chemotherapy (FEC or CMF) (DM: 11%, LNM: 43%).
Two patients in the LMN group received neoadjuvant
chemotherapy (FEC). For patients with lymph node me-
tastasis, the axillary surgery was performed either at the
same time as primary surgery, or in the following 2–3
weeks, after cancer cells was detected in sentinel node, or
other pathologic indication for additional surgery. Patients
with distant metastasis were operated for the second time
0–11 years after the primary surgery. In one case, a skin
metastasis was found and removed before performing
mastectomy. The indication for secondary surgery and re-
moving a distant metastasis could be a pathologic fracture,
an unknown skin lesion or to obtain diagnosis for an un-
known tumour.
Tumour samples were directly put on ice during surgery
and stored in −80°C until analysis. A slide was taken from
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tastasis, and stained with haematoxylin and eosin and
verified to have cancer tissue present. Follow-up and pa-
tient data was obtained through examination of patient re-
cords and from tumour analysis performed at the bio
bank. The study was approved by the ethical committee of
Lund University (LU 240–01).
Clinico-pathological variables
Oestrogen receptor (ER) status was obtained from routine
pathologic examination with immunohistochemistry (IHC)
with a cut off of 10% or from an enzyme immuno-assay
with a cut off of 25 fmol/mg protein.
Sample preparation
Frozen tissue samples were pulverised in bead beater
4 × 1 min at the highest speed and lysed with 0.5 ml lysis
buffer (50% 2,2,2-Trifluoroethanol (TFE), 50% PBS).
RapiGest, 1% in 100 mM ammonium bicarbonate was
added to the samples and the lysates were centrifuged at
2000 g for 30 min, at 4°C, after which supernatant was
incubated at 60°C, with shaking for 2 hours. Samples
were then centrifuged at 2000 g for 10 min, at RT and
supernatant was reduced and alkylated by incubation
with 5 mM DTT at 60°C, 800 rpm for 30 min followed
by incubation with 25 mM IAA at RT, in dark for
30 min. Samples were digested with 7.9 mg/ml Trypsin
at 37°C, 1000 rpm, overnight. The digest was submitted
to reverse-phase clean up in 500 mg C18 cartridge. The
peptides were eluted from the cartridge with 0.1% FA in
50% ACN and the flow-through was concentrated in a
SpeedVac, to 100 μl final volume.
Sample modification and digestion
Samples were diluted with oxidation buffer and sodium
meta-periodate in water was added to the sample to a
8 mM concentration and samples incubated at 6°C, dark
at 600 rpm for exactly 60 minutes. Reverse-phase clean
up of digest was performed again and samples were con-
centrated in SpeedVac to about 400 μl. 500 μl of the
supplied 50% slurry in isopropanol was washed with
3x500 μl of water; 3x500 μl of coupling buffer and after
which the resins were diluted with coupling buffer to a
50%-slurry. The concentrated samples were resuspended
with 400 μl coupling buffer and pH adjusted to 4.5 and
then 500 μl of the 50%-slurry in coupling buffer was
added to each sample and incubated at head-over rota-
tion, RT overnight. Supernatant was collected by centri-
fugation (non-bound peptides) and resin washed with
2×500 μl of coupling buffer and collected into the same
tube (glycopeptides).
Samples were washed with 5×500 μl each of 5 M so-
dium chloride, HPLC-H2O, 80% ACN, Methanol, HPLC-
H2O and 100 mM ammonium bicarbonate. The resinswere transferred to a new Eppendorff tube with 300 μl
100 mM Ammonium bicarbonate buffer, pH 8.0. PNGase
F (5 μl of a 1U/μl) was added to the resin, pH adjusted to
8.0 and resins incubated at 37°C. After the incubation, pH
was adjusted to 8.0, samples centrifuged at briefly in a
mini-Eppendorf centrifuge for 30 sec and these formerly
N-glycosylated peptides, collected by pipetting into a new
tube. The resins were washed 2× with 500 μl 80% ACN,
and flow-through combined with the previous one. Sam-
ples were then dried in SpeedVac, to volume of 100 μl.
Reverse-phase clean up of digest was performed again,
peptides eluted with 0.5 ml 0.1% FA/50% ACN into a new
tube and then dried completely in Speed-Vac. Dried sam-
ples were resuspended with 20 μl of 0.1%FA/0.3% ACN in
HPLC-grade water.
Mass spectrometry analysis
An ESI-LTQ-Orbitrap XL mass spectrometer (Thermo
Electron, Bremen, Germany) interfaced with an Eksigent
nanoLC plus HPLC system (Eksigent technologies, Dublin,
CA, USA) was used for all analyses. Peptides were loaded a
constant flow rate of 10 μl/min onto a pre-column (PepMap
100, C18, 5 μm, 5 mm×0.3 mm, LC Packings, Amsterdam,
Netherlands) and subsequently separated on a 10 μm fused
silica emitter, 75 μm×16 cm (PicoTip™ Emitter, New
Objective, Inc. Woburn, MA, USA), packed in-house with
Reprosil-Pur C18-AQ resin (3 μm Dr. Maisch GmbH,
Ammerbuch-Entringen, Germany). Peptides were eluted
with a 150 min for label-free quantification linear gradient
of 3 to 35% acetonitrile in water, containing 0.1% formic
acid, with a flow rate of 300 nl/min.
The LTQ-Orbitrap was operated in a data-dependent
mode simultaneously acquiring MS spectra in the Orbitrap
(from m/z 400 to 2000) and MS/MS spectra in the LTQ.
Four MS/MS spectra were acquired using CID (collision in-
duced dissociation) in the LTQ and each Orbitrap-MS scan
was acquired at 60,000 FWHM nominal resolution settings
using the lock mass option (m/z 445.120025) for internal
calibration. The normalized collision energy was set to 35%
for CID. The dynamic exclusion list was restricted to 500
entries using a repeat count of two with a repeat duration
of 20 seconds and with a maximum retention period
120 seconds. Precursor ion charge state screening was en-
abled to select for ions with at least two charges and
rejecting ions with undetermined charge state.
Data analysis
Raw mass spectrometric data was independently ana-
lysed in Progenesis LC-MS (Nonlinear Dynamics Ltd,
version 4.1.4804) and Proteios SE (version 2.19.0) soft-
ware platforms. In both cases, runs were aligned and
peptide identifications were propagated between runs in
order to minimize missing values. MS/MS spectra of
ions with charge +2/+3/+4 between 400–1000 m/z and
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identification using the UniProt database release 2012
filtered for human. Identifications were filtered with an
FDR of 0.05 at the peptide and protein levels. Only pep-
tides showing an Asn to Asp conversion with a consen-
sus sequence of NX(S/T) were used for subsequent
analysis. Only proteins with at least one unique peptide
were kept in the dataset. Qlucore Omics Explorer (Qlu-
core AB, version 2.3) software was used for statistical
analysis of the protein expression profiles. The func-
tional enrichment and pathway analysis was carried out
with MetaCore™ (Thomson Reuters, version 6.14).Statistical analysis
Normalized protein abundances (by Total Ion Current in
the area of analysis) were used for the analysis. The abun-
dances were log2 transformed. For each sample, the average
log2 abundance over two technical replicates was calcu-
lated. A pairwise t-test for each protein was made between
the primary and metastasis tumours for both the lymph
node and the distant groups. Patients with missing values
were removed for these calculations. Histograms of the p-
values were made for both the lymph node and the distant
metastasis groups. The histograms have a high count at low
p-values showing that there are significant differences be-
tween the primary and metastasis tumours after multiple
hypothesis correction. Principal component analysis (PCA)
plots were made for both the distant and lymph node tu-
mours. For each pair of primary and metastasis tumour
from the same patient, the correlation distance between the
two tumours was calculated. A box plot was made for the
pair distances comparing the lymph node and distant
groups. The mean value of the distance between pairs
shows no significant difference, but the variance is higher
in the lymph node metastasis group (p-value = 0.05, F test).
For IHC analysis, the Wilcoxon signed-rank test was used.
All computations were done in R.Immunohistochemical analysis
A previously constructed tissue microarray (TMA) was
used for immunohistochemistry verification. Details and
patient characteristics are found in the original study
[30,31]. In brief, 552 primary tumours, 159 axillary syn-
chronous lymph node metastases and 51 asynchronous
metastases (locoregional or distant), were collected. From
the donor paraffin block two tissue cylinders of 1.0 mm
were taken from a representative area of the tissue and
transferred to a recipient paraffin block. The TMA blocks
were cut into 3–4 μm thick sections and mounted on to
glass slides (SuperFrost Plus, Menzel-Gläser, Gerhard
Menzel GmbH, Braunschweig, Germany), the glasses were
let to dry at room temperature and baked in a heat cham-
ber at 60°C for 2 hours.The following monoclonal antibodies were used: mouse
anti-cytokeratin 17 (1:30, Dako, Glostrup, Denmark),
rabbit anti-CD82 (1:500, Cell Signalling Technologies,
USA) rabbit anti-β-tubulin (1:300, Cell Signalling Tech-
nologies, USA), rabbit anti-ATPIF1 (1:1500, Cell Signalling
Technologies, USA) and mouse anti-thrombomodulin
(1:10, Dako, Glostrup, Denmark). Slides with cytokeratin
17, CD82 and tubulin β-chain were placed in EnVision™
FLEX buffer with pH 9 (Dako, Glostrup, Denmark) heated
in a PT-Link (Dako, Glostrup, Denmark) to 65°C, then
98°C for 20 min and decreased to 65°C. Slides with
ATPase inhibitory factor 1 (ATPIF1) and Thrombomodulin
were deparaffinised using xylene, 99% and 96% ethanol,
placed in a pH 6 Target Retrieval Solution (Dako, Glostrup,
Denmark). Subsequently, the slides were placed in a
Pressure Cooker 2100 Retriever (Histolab Products AB,
Gothenburg, Sweden) in 125°C for 5 minutes and then
let to cool. Staining was performed with EnVision™
FLEX, High pH (Dako, Glostrup, Denmark) in an auto-
matic immunohistochemistry staining machine (Dako,
Glostrup, Denmark). All antibodies were incubated with
the slides for 30 minutes, except the β-tubulin slides,
which were incubated for 60 minutes. Counterstaining
was performed using REAL™ Haematoxylin (Dako,
Glostrup, Denmark) for 2 minutes. Sections were dehy-
drated and mounted with coverslips.
Protein levels were scored with a light microscope under
the supervision of a pathologist. Cores were scored for in-
tensity in 5 levels (0–4) and proportion as percentage of
positive cells. The average between cores were calculated for
each tumour and used for further analysis. An average pro-
portion <10% were regarded as negative (intensity level 0),
otherwise intensity was used for analysis. Pairs of primary
and synchronous lymph node or asynchronous metastases
missing data from one of the tumour types were excluded.
Primary tumours and synchronous lymph node metastasis
were scored. Asynchronous metastases were scored if mass
spectrometry analysis showed differential regulation between
primary tumour and distant metastasis.
Additional file
Additional file 1: Figure S1. Metacore analysis showing the proteins
found that are involved in the development of ligand independent
oestrogen receptor activation. (a) The change in expression relative to
the primary tumour is indicated by the thermometers next to the protein
representation for ER+ lymph node metastases (1) and ER- lymph node
metastases (2). EGFR (Epidermal growth factor receptor, HER2), ErbB2
(Receptor tyrosine-protein kinase erbB-2) ErbB3 (Receptor tyrosine-protein
kinase erbB-3), IGFR1 (insulin-like growth factor receptor-1), Shc (Shc
transforming protein-1), NCOA2 (nuclear receptor co-activator-2), TFF1
(Trefoil factor 1) and PKA-reg (protein kinase A regulatory subunit). (b)
The change in expression, relative to the primary tumour, is indicated
by the thermometers next to the protein representation for ER+ distant
metastasis (1) and ER- distant metastasis (2)-. (c) The change in expression,
relative to the primary tumour, is indicated by the thermometers next to the
protein representation for ER- lymph node metastasis (1) and ER- distant (2)
Kurbasic et al. Clinical Proteomics  (2015) 12:13 Page 13 of 14metastases. (d) The change in expression, relative to the primary tumour, is
indicated by the thermometers next to the protein representation for ER+
lymph node metastasis (1) and ER+ distant (2) metastases.
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